CDKN2B-AS1 and gastric cancer: The results revealed that ANRIL expression was an independent prognostic indicator for DFS (HR=1.717, 95% CI, 1.036-2.844; P=0.036) and OS (HR=1.743, 95% CI, 1.036-2.933; P=0.036) in patients with gastric cancer (Table 2).